Vivoryon Therapeutics AG (GB:0R3M) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Vivoryon Therapeutics has reported promising results from its Phase 2 studies on varoglutamstat, showcasing significant improvements in kidney function for patients. The company highlights the potential of varoglutamstat as a treatment for diabetic kidney disease, with plans to advance its clinical development. Financially, Vivoryon anticipates sufficient funds to support operations until Q3 2025, reflecting a strong position for further growth.
For further insights into GB:0R3M stock, check out TipRanks’ Stock Analysis page.